The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3/4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to pharmaceutical composition of these compounds and methods of preparation and use thereof.
该发明提供了一类新型的HCV治疗药物,这些药物是口服可用的,安全有效的HCV
NS3/4A蛋白酶抑制剂,并且比现有治疗药物更不容易产生药物抗性。该发明还涉及这些化合物的药物组合物以及其制备和使用方法。